alexa Suggamadex Produce Neuron Cell Death in Primary Culture | OMICS International
ISSN: 2167-0870
Journal of Clinical Trials
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Suggamadex Produce Neuron Cell Death in Primary Culture

Soraya L Valles*
Department of Physiology, University of Valencia, Spain
Corresponding Author : Dr. Soraya L Valles
Department of Physiology
Faculty of Medicine, University of Valencia, Spain
E-mail: [email protected]
Received November 06, 2012; Accepted November 06, 2012; Published November 08, 2012
Citation: Valles SL (2012) Suggamadex Produce Neuron Cell Death in Primary Culture. J Clin Trials 1:e111. doi:10.4172/2167-0870.1000e111
Copyright: © 2012 Valles SL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical Trials

Sugammadex, a γ-cyclodextrin that encapsulates selectively steroidal neuromuscular blocking agents, such as rocuronium or vecuronium, has changed the face of clinical neuromuscular pharmacology. Sugammadex allows a rapid reversal of muscle paralysis. After its injection, a train-of-four ratio >0.9 is obtained in less than 5 minutes in all patients, whatever the degree of muscle paralysis and even when anesthesia is maintained with halogenated agents. Sugammadex in blood-brain barrier penetration is poor (<3% in rats). However the blood brain barrier permeability can be altered under different conditions (i.e. neurodegenerative diseases, trauma, ischemia, infections, or immature nervous system). We show here that clinically relevant sugammadex concentrations cause apoptotic neuron death in primary cultures.
A Cochrane systematic review including 18 randomized controlled trials (with a total of 1321 patients) on the efficacy and Safety of Sugammadex (SUG) concluded that it was more effective than placebo (no medication) or neostigmine in reversing muscle relaxation caused by Neuromuscular Blockade (NMB) during surgery and is relatively safe. Serious complications occurred in less than 1% of the patients who received SUG [1]. Reported side effects for SUG included cough, dry mouth, temperature changes, parasomia, paresthesia, movement during surgery, mild erythemia, abdominal discomfort, tachycardia, bradycardia, dizziness, increased creatinine phosphokinase, and increased B2 microglobinuria [2]. Pooled preclinical safety data obtained from the US FDA briefing document [3]; and the European Medicines Agency scientific document [4] reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction, local tolerance or compatibility with blood. Potential kidney and lung toxicity of cyclodextrins, if large repeated doses are administered, must be also taken into account [5]. Besides, available information regarding SUG on special conditions/population, including renal impairment, elderly patients, obese patients, and pediatric population is really limited [3,4,6].
SUG exhibits a very low transfer across the Blood-Brain Barrier (BBB) and the placenta. Nevertheless, different clinical conditions imply moderate or severe alterations of the BBB integrity, i.e. Alzheimer [7], Parkinson [8] or multiple sclerosis [9] disease-associated neurodegeneration, traumatic brain/spinal cord injury [10], ischemia [11], meningitis [12], or immature nervous system [13]. Under these clinical conditions, SUG may cross the BBB in specific areas. SUG can act such as potential induced neuronal toxicity.
SUG causes cell death, predominantly by apoptosis, in cultured neurons [14,15]. Apoptosis induction associates with an alteration in neuronal cholesterol homeostasis [15]. In fact, neuronal death caused by inhibition of intracellular cholesterol trafficking has been shown to be caspase dependent and associated with activation of the mitochondrial apoptosis pathway [16]. Cholesterol is an abundant component of plasma membranes of eukaryotic cells and is an essential regulator of membrane fluidity, permeability, receptor function, and ion channel activity [17].
Nevertheless cholesterol accumulation may be a double edge sword since, as other reports suggest, excessive accumulation of cholesterol in mitochondria may be a key step in promoting e.g. Alzheimer disease progression [18]. In this scenario U18666A, a cholesterol transportinhibiting agent, leads to high intracellular cholesterol accumulation in primary cortical neurons, activation of caspases and calpains, hyperphosphorylation of tau, and apoptosis [19].
The potential association of SUG-induced alteration in cholesterol homeostasis with oxidative stress and apoptosis activation, the fact that resistance/sensitivity to oxidative stress may likely differ between brain regions and neuronal cell types, potential neurons-astrocytes interactions, as well as modulation by pathological mechanisms such as inflammation, all represent new research windows that deserve further studies.
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11718
  • [From(publication date):
    December-2012 - Jan 17, 2018]
  • Breakdown by view type
  • HTML page views : 7961
  • PDF downloads : 3757
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

medicaljou[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version